Nir Sharon

19 Giborei Israel Blvd, 4250419
Netanya, M 42504, Israel

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

Characterization of local tolerability of TV-46000, a long-acting subcutaneous formulation of risperidone for the treatment of schizophrenia.

Characterization of local tolerability of TV-46000, a long-acting subcutaneous formulation of risperidone for the treatment of schizophrenia.

Journal: Journal of psychiatric research

Published: March 06, 2026

Correction: Effects of Long-Term Treatment with TV-46000 on Symptom Improvement Over Time in Stabilized Patients with Schizophrenia.

Correction: Effects of Long-Term Treatment with TV-46000 on Symptom Improvement Over Time in Stabilized Patients with Schizophrenia.

Journal: CNS drugs

Published: January 14, 2026

Effects of Long-Term Treatment with TV-46000 on Symptom Improvement Over Time in Stabilized Patients with Schizophrenia.

Effects of Long-Term Treatment with TV-46000 on Symptom Improvement Over Time in Stabilized Patients with Schizophrenia.

Journal: CNS drugs

Published: May 30, 2025

Safety Outcomes with the Long-Acting Subcutaneous Antipsychotic TV-46000 in Schizophrenia: A Post Hoc Analysis of Behavioral, Neuromotor, Endocrine, and Cardiometabolic Outcomes from Two Phase 3 Studies.

Safety Outcomes with the Long-Acting Subcutaneous Antipsychotic TV-46000 in Schizophrenia: A Post Hoc Analysis of Behavioral, Neuromotor, Endocrine, and Cardiometabolic Outcomes from Two Phase 3 Studies.

Journal: CNS drugs

Published: May 26, 2025

Safety, Tolerability, and Pharmacokinetics of Subcutaneous Extended-Release Injectable Olanzapine in Patients with Schizophrenia and Schizoaffective Disorder.

Safety, Tolerability, and Pharmacokinetics of Subcutaneous Extended-Release Injectable Olanzapine in Patients with Schizophrenia and Schizoaffective Disorder.

Journal: Clinical drug investigation

Published: May 21, 2025

Clinical Benefit and Risk Profile of TV-46000 for Patients with Schizophrenia as Assessed by Number Needed to Treat and Number Needed to Harm.

Clinical Benefit and Risk Profile of TV-46000 for Patients with Schizophrenia as Assessed by Number Needed to Treat and Number Needed to Harm.

Journal: Neuropsychiatric disease and treatment

Published: April 16, 2025

Outlier removal in cryo-EM via radial profiles.

Outlier removal in cryo-EM via radial profiles.

Journal: Journal of structural biology

Published: September 15, 2024

A Long-Term Safety and Tolerability Study of TV-46000 for Subcutaneous Use in Patients with Schizophrenia: A Phase 3, Randomized, Double-Blinded Clinical Trial.

A Long-Term Safety and Tolerability Study of TV-46000 for Subcutaneous Use in Patients with Schizophrenia: A Phase 3, Randomized, Double-Blinded Clinical Trial.

Journal: CNS drugs

Published: June 06, 2024

Centering Noisy Images with Application to Cryo-EM.

Centering Noisy Images with Application to Cryo-EM.

Journal: SIAM journal on imaging sciences

Published: February 07, 2022

Efficacy and safety of TV-46000, a long-acting, subcutaneous, injectable formulation of risperidone, for schizophrenia: a randomised clinical trial in the USA and Bulgaria.

Efficacy and safety of TV-46000, a long-acting, subcutaneous, injectable formulation of risperidone, for schizophrenia: a randomised clinical trial in the USA and Bulgaria.

Journal: The lancet. Psychiatry

Published: January 10, 2022

Method of moments for 3D single particle ab initio modeling with non-uniform distribution of viewing angles.

Method of moments for 3D single particle ab initio modeling with non-uniform distribution of viewing angles.

Journal: Inverse problems

Published: April 01, 2020

A Randomized Controlled Study to Determine the Efficacy of Garlic Compounds in Patients With Hematological Malignancies at Risk for Chemotherapy-Related Febrile Neutropenia.

A Randomized Controlled Study to Determine the Efficacy of Garlic Compounds in Patients With Hematological Malignancies at Risk for Chemotherapy-Related Febrile Neutropenia.

Journal: Integrative cancer therapies

Published: June 04, 2015

Showing 1-12 of 12

Last Updated: 09/26/2026